Phase 2 trial of temozolomide using protracted low-dose and whole-brain radiotherapy for nonsmall cell lung cancer and breast cancer patients with brain metastases

Cancer

Volumn 113, Issue 9, 2008, Pages 2524-2531

  Addeo, Raffaele ^a   De Rosa, Carmine ^b   Faiola, Vincenzo ^a   Leo, Luigi ^c   Cennamo, Gregorio ^a   Montella, Liliana ^a   Guarrasi, Rosario ^a   Vincenzi, Bruno ^d   Caraglia, Michele ^e   Prete, Salvatore Del ^a  

^a SAN GIOVANNI DI DIO HOSPITAL   (Italy)

^b San Giovanni Bosco Hospital   (Italy)

^c Piedimonte Matese Hospital   (Italy)

^d Biomedical University   (Italy)

^e SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

Brain metastases; Metronomic therapy; Temozolomide; Whole brain radiotherapy

Indexed keywords

TEMOZOLOMIDE;

ADULT; AGED; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BRAIN FUNCTION; BRAIN METASTASIS; BREAST CANCER; CANCER RADIOTHERAPY; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EPISTAXIS; FEMALE; HEADACHE; HUMAN; INFECTION; LIVER TOXICITY; LUNG NON SMALL CELL CANCER; MALE; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEPHROTOXICITY; NEUROPATHIC PAIN; NEUTROPENIA; PETECHIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RADIATION DOSE; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VOMITING;

AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; BONE MARROW; BRAIN NEOPLASMS; BREAST NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; COMBINED MODALITY THERAPY; CRANIAL IRRADIATION; DACARBAZINE; FEMALE; HUMANS; LIVER NEOPLASMS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; REMISSION INDUCTION; SURVIVAL RATE;

EID: 55549112218     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.23859     Document Type: Article

References (37)

1. Hutter A, Schwetye K, Bierhals A, McKinstry R. Brain neoplasms: epidemiology, diagnosis, and prospects for cost-effective imaging. Neuroimaging Clin N Am. 2003;2:237-250.
2. Omuro AM, Abrey LE. Brain metastases. Curr Neurol Neurosci Rep. 2004;4:205-210.
3. Lin NU, Bellon JR, Winer EP. CNS metastases in breast cancer. J Clin Oncol. 2004;22:3608-3617.
4. Jeyapalan SA, Batchelor T. Management of brain metastases. Curr Treat Options Neurol. 2004;6:273-284.
5. Soffietti R, Cornu P, Delattre JY, et al. EFNS guidelines on diagnosis and treatment of brain metastases: report of an EFNS Task Force. Eur J Neurol. 2006;13:674-681.
6. Eichler AF, Loeffler JS. Multidisciplinary management of brain metastases. Oncologist. 2007;12:884-898.
7. Baker SD, Wirth M, Statkevich P, et al. Absorption, metabolism, and excretion of 14C-temozolomide following oral administration to patients with advanced cancer. Clin Cancer Res. 1999;5:309-317.
8. Raymond E, Izbicka E, Soda H, et al. Activity of temozolomide against human tumor colony-forming units. Clin Cancer Res. 1997;3:1769-1774.
9. Christodoulou C, Bafaloukos D, Kosmidis P, et al. Phase II study of temozolomide in heavily pretreated cancer patients with brain metastases. Ann Oncol. 2001;12:249-254.
10. Abrey LE, Olson JD, Raizer JJ, et al. A phase II trial of temozolomide for patients with recurrent or progressive brain metastases. J Neurooncol. 2001;53:259-265.
11. Cortot AB, Geriniere L, Robinet G, et al. Phase II trial of temozolomide and cisplatin followed by whole brain radiotherapy in non-small-cell lung cancer patients with brain metastases: a GLOT-GFPC study. Ann Oncol. 2006;17:1412-1417.
12. Trudeau ME, Crump M, Charpentier D, et al. Temozolomide in metastatic breast cancer (MBC): a phase II trial of the National Cancer Institute of Canada - Clinical Trials Group (NCIC-CTG). Ann Oncol. 2006;17:952-956.
13. Antonadou D, Paraskevaidis M, Sarris M, et al. Phase II randomized trial of temozolomide and concurrent radiotherapy in patients with brain metastases. J Clin Oncol. 2002;20:3644-3650.
14. Verger E, Gil M, Yaya R, et al. Temozolomide and concomitant whole brain radiotherapy in patients with brain metastases: a phase II randomized trial. Int J Radiat Oncol Biol Phys. 2005;61:185-191.
15. Addeo R, Caraglia M, Faiola V, et al. Concomitant treatment of brain metastasis with whole brain radiotherapy [WBRT] and temozolomide [TMZ] is active and improves quality of life. BMC Cancer. 2007;7:18.
16. Newlands ES, Blackledge GR, Slack JA, et al. Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856). Br J Cancer. 1992;65:287-291.
17. Caraglia M, Addeo R, Costanzo R, et al. Phase II study of temozolomide plus pegylated liposomal doxorubicin in the treatment of brain metastases from solid tumours. Cancer Chemother Pharmacol. 2006;57:34-39.
18. Rivera E, Meyers C, Groves M, et al. Phase I study of capecitabine in combination with temozolomide in the treatment of patients with brain metastases from breast cancer. Cancer. 2006;107:1348-1354.
19. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2006;92:205-216.
20. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
21. Simon R. Optimal 2-stage designs for phase II clinical trials. Control Clin Trials. 1989;10:1-10.
22. Yawn BP, Wollan PC, Schroeder C, et al. Temporal and gender-related trends in brain metastases from lung and breast cancer. Minn Med. 2003;86:32-37.
23. Khuntia D, Brown P, Li J, Mehta MP. Whole brain radiotherapy in the management of brain metastasis. J Clin Oncol. 2006;24:1295-1304.
24. Dziadziuszko R, Ardizzoni A, Postmus PE, et al. Temozolomide in patients with advanced non-small cell lung cancer with or without brain metastases: a phase II study of the EORTC lung cancer group. Eur J Cancer. 2003;39:1271-1276.
25. Quantin X, Khial F, Reme-Saumon M, et al. Concomitant brain radiotherapy and vinorelbine-ifosfamide-cisplatin chemotherapy in brain metastases of non-small-cell-lung cancer. Lung Cancer. 1999;26:35-39.
26. Gasperini G. Metronomic scheduling: the future of chemotherapy? Lancet Oncol. 2001;2:733-740.
27. Shaked Y, Emmenegger U, Francia G, et al. Low-dose metronomic combined with intermittent bolus-dose cyclophosphamide is an effective long-term chemotherapy treatment strategy. Cancer Res. 2005;65:7045-7051.
28. Tuettenberg J, Grobholz R, Korn T, et al. Continuous low-dose chemotherapy plus inhibition of cyclooxygenase-2 as an antiangiogenic therapy of glioblastoma multiforme. J Cancer Res Clin Oncol. 2005;131:31-40.
29. Kim JT, Kim JS, Ko KW, et al. Metronomic treatment of temozolomide inhibits tumor cell growth through reduction of angiogenesis and augmentation of apoptosis in orthotopic models of gliomas. Oncol Rep. 2006;16:33-39.
30. Zhou Q, Guo P, Wang X, et al. Preclinical pharmacokinetic and pharmacodynamic evaluation of metronomic and conventional temozolomide dosing regimens. J Pharmacol Exp Ther. 2007;321:265-275.
31. 6-alkylguaninae-DNA alkyltransferase activity with protracted temozolomide schedules. Br J Cancer. 2003;88:1004-1011.
32. Brock CS, Newlands ES, Wedge SR, et al. Phase I trial of temozolomide using an extended continuous oral schedule. Cancer Res. 1998;58:4363-4367.
33. Omuro AM, Raizer JJ, Demopoulos D, et al. Vinorelbine combined with a protracted course of temozolomide for recurrent brain metastasis: a phase I trial. J Neurooncol. 2006;78:277-280.
34. Gaspar LE, Scott C, Rotman M, et al. Recursive partitioning analysis (RPA) of prognostic factors in 3 Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys. 1997;37:745-751.
35. Langer CJ, Mehta MP. Current management of brain metastases, with a focus on systemic options. J Clin Oncol. 2005;23:6207-6219.
36. Taimur S, Edelman MJ. Treatment options for brain metastases in patients with non-small-cell lung cancer. Curr Oncol Rep. 2003;5:342-346.
37. Kuo T, Recht L. Optimizing therapy for patients with brain metastases. Semin Oncol. 2006;33:299-306.